Syri Limited trading as SyriMed, is a UK-based specialty pharmaceutical company dedicated to developing innovative and value-added medicines, including unlicensed medicines (Specials). We specialise in improving generic molecules through advanced proprietary formulations adapted to the clinical needs of patients to improve their care and ease of administration, particularly in critical conditions like epilepsy. Our liquid medicines offer precise dosing for patients who struggle with tablets, including children and those with dysphagia.